Tandem Diabetes Care Inc
NASDAQ:TNDM
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
19.05
53.43
|
| Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Tandem Diabetes Care Inc
Tandem Diabetes Care Inc
Capital Expenditures
Tandem Diabetes Care Inc
Capital Expenditures Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Capital Expenditures | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Tandem Diabetes Care Inc
NASDAQ:TNDM
|
Capital Expenditures
-$43.7m
|
CAGR 3-Years
-26%
|
CAGR 5-Years
-26%
|
CAGR 10-Years
-20%
|
|
|
Becton Dickinson and Co
NYSE:BDX
|
Capital Expenditures
-$725m
|
CAGR 3-Years
15%
|
CAGR 5-Years
5%
|
CAGR 10-Years
-1%
|
|
|
Boston Scientific Corp
NYSE:BSX
|
Capital Expenditures
-$780m
|
CAGR 3-Years
-15%
|
CAGR 5-Years
-8%
|
CAGR 10-Years
-10%
|
|
|
Stryker Corp
NYSE:SYK
|
Capital Expenditures
-$634m
|
CAGR 3-Years
-9%
|
CAGR 5-Years
-1%
|
CAGR 10-Years
-11%
|
|
|
Abbott Laboratories
NYSE:ABT
|
Capital Expenditures
-$2.2B
|
CAGR 3-Years
-5%
|
CAGR 5-Years
-6%
|
CAGR 10-Years
-7%
|
|
|
Intuitive Surgical Inc
NASDAQ:ISRG
|
Capital Expenditures
-$1.2B
|
CAGR 3-Years
-67%
|
CAGR 5-Years
-29%
|
CAGR 10-Years
-33%
|
|
Tandem Diabetes Care Inc
Glance View
Tandem Diabetes Care, Inc. engages in the design, development, and commercialization of products for people with insulin-dependent diabetes. The company is headquartered in San Diego, California and currently employs 2,000 full-time employees. The company went IPO on 2013-11-13. The firm is focused on the design, development, and commercialization of technology solutions for people living with diabetes. The firm's manufacturing, sales, and support activities principally focus on its flagship pump platform, the t:slim X2, and its complementary product offerings. Its t:slim X2 is based on Company's technology platform and is the smallest durable insulin pump available in the United States. The firm has commercially offered two different automated insulin dosing (AID) algorithms on t:slim X2, including Control-IQ technology, which is an advanced hybrid-closed loop feature, designed to help increase a user's time in their targeted glycemic range, and Food and Drug Administration (FDA) to deliver automatic correction boluses in addition to adjusting insulin to help prevent high and low blood sugar based on continuous glucose monitoring (CGM) readings.
See Also
What is Tandem Diabetes Care Inc's Capital Expenditures?
Capital Expenditures
-43.7m
USD
Based on the financial report for Sep 30, 2024, Tandem Diabetes Care Inc's Capital Expenditures amounts to -43.7m USD.
What is Tandem Diabetes Care Inc's Capital Expenditures growth rate?
Capital Expenditures CAGR 10Y
-20%
Over the last year, the Capital Expenditures growth was -47%. The average annual Capital Expenditures growth rates for Tandem Diabetes Care Inc have been -26% over the past three years , -26% over the past five years , and -20% over the past ten years .
You don't have any saved screeners yet
